Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder

Overactive Bladder Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00461292
• Other study ID #: 191622-516
• Status: Completed
• Phase: Phase 3
• First received: April 13, 2007
• Last updated: September 17, 2015
• Start date: May 2007
• Est. completion date: April 2010

Study information

• Verified date: September 2015
• Source: Allergan
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients

Recruitment information / eligibility

• Status: Completed
• Enrollment: 275
• Est. completion date: April 2010
• Est. primary completion date: March 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis

• Inadequate response to anticholinergic medication used to treat overactive bladder

Exclusion Criteria:

• History or evidence of pelvic or urologic abnormality

• Previous or current diagnosis of bladder or prostate cancer

• Urinary tract infection at time of enrollment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Biological:
• botulinum toxin Type A (200U)
botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
• botulinum toxin Type A (300U)
botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor

Other:
• Normal saline (Placebo); botulinum toxin Type A (200U)
Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
• Normal saline (Placebo); botulinum toxin Type A (300U)
Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Allergan

Countries where clinical trial is conducted

United States,  Brazil,  Canada,  France,  Italy,  Netherlands,  Portugal,  Singapore,  South Africa,  Spain,  Taiwan,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline in Number of Weekly Episodes of Urinary Incontinence	Change from baseline in the weekly frequency of incontinence episodes at Week 6 after the first treatment. Incontinence is defined as involuntary loss of urine as recorded in a patient bladder diary. A negative number change from baseline indicates a reduction in incontinence episodes (improvement).	Baseline, Week 6	No
Secondary	Change From Baseline in Maximum Cystometric Capacity (MCC)	Change from baseline in MCC at Week 6. MCC represents the maximum volume of urine the bladder holds. A positive number change from baseline represents an improvement (increase) in maximum volume of urine the bladder holds.	Baseline, Week 6	No
Secondary	Change From Baseline in Maximum Detrusor Pressure (MDP)	Change from baseline in MDP during the first involuntary detrusor contraction at week 6. MDP represents the maximum pressure (peak amplitude) in the bladder during the first involuntary contraction of the bladder muscle. The greater the negative number change from baseline, the better the improvement.	Baseline, Week 6	No
Secondary	Change From Baseline in Total Score on Incontinence Quality of Life (I-QOL) Questionnaire	Change from baseline in I-QOL questionnaire total score at Week 6, as completed by the patient. The I-QOL is a validated, disease-specific quality of life (QOL) questionnaire containing 22 questions designed to measure impact of urinary incontinence on patients' lives. Each question is answered on a 5-point scale (1 = worst QOL, and 5 = best QOL). The scores are totaled over the 22 questions and normalized to a score of 0-100 (0=worst QOL and 100=best QOL). A positive change from baseline represents an improvement.	Baseline, Week 6	No